Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274003 | 0.93 | CHRM3 (0.65) | CHRM3 | |
| SCHEMBL272766 | 0.88 | CHRM3 (0.65) | CHRM3 | |
| SCHEMBL273385 | 0.88 | CHRM3 (0.65) | CHRM3 | |
| SCHEMBL272710 | 0.87 | CHRM3 (0.62) | CHRM3 | |
| Hydrochloric Acid SCHEMBL272709 | 0.86 | CHRM3 (0.61) | CHRM3 | |
| SCHEMBL272784 | 0.85 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL385069 | 0.84 | CHRM3 (0.59) | CHRM3 | |
| SCHEMBL18239912 | 0.84 | CHRM3 (0.59) | CHRM3 | |
| SCHEMBL730320 | 0.82 | CHRM3 (0.57) | CHRM3 | |
| SCHEMBL278884 | 0.82 | CHRM3 (0.77) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010489-B1 | DIALKYLPHENYL COMPOUNDS HAVING 2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8134006-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134006-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134006-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2010490-B1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | THERAVANCE INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110086881-A1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | THERAVANCE, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-7880010-B2 | form 1 of crystalline free base of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester; useful for treating pulmonary disorders, such as asthma and chronic obstructive pulmonary disease | THERAVANCE, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687521-B2 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-09 | — | — | US | disclosed |
| US-7524965-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-2010490-A2 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | Theravance, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-2010489-A2 | DIALKYLPHENYL COMPOUNDS HAVING 2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007127297-A2 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | THERAVANCE, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127196-A2 | DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249674-A1 | Crystalline forms of a dimethylphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249674-A1 | Crystalline forms of a dimethylphenyl compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, PKD1 | CHRM3 599/4885 |
| US-20110086881-A1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, PKD1 | CHRM3 599/4885 |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | CHRM3 11/4885 |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | CHRM3 11/4885 |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB2, ADRB1, ADRA2C | CHRM3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.